Arbutus Biopharma Corp (ABUS)

R&D Expense Growth

-29.66%

Quarterly · Period ending:

ABUS logo

ABUS R&D Expense Growth

Latest reported-29.66%
ABUS Quarterly R&D Growth (QoQ) (0.00% → -29.66%)
High-resolution chart · PNG

ABUS r&d expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Arbutus Biopharma Corp R&D Expense Growth — Quarterly
Period endingR&D Expense Growth
-29.6602%
-17.6988%
-13.361%
5.0928%
-38.6315%
1.6913%
-38.2751%
-8.2181%
0.9609%
-12.3036%
-12.9159%
14.0007%
-3.1902%
-20.3669%
14.4303%
-12.5839%
24.2661%
-3.9038%
14.98%
5.7599%
14.635%
-15.9224%
35.8641%
15.2891%
0.4704%
-81.484%
217.2635%
39.1758%
-13.404%
32.9838%
-33.2186%
1.2839%
17.2557%
-21.7316%
14.7068%
0.5957%
11.3394%
-19.142%
9.01%
3.4374%
15.7562%
-11.8089%
-8.8663%
68.5979%
-8.1178%
-11.3006%
27.8548%
0.1183%
13.335%
17.2939%
27.2318%
14.2914%
16.8325%
-100%
572,623,539.8309%
0%
0%
0%
0%
0%
0%
-100%
437,286,749.8767%
0%
0%
0%
0%
0%
0%
0%
-100%
-7.6154%
0%
-100%
-4.4098%
235.8149%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.